Is Wall Street to blame for lack of new drugs?

Fortune scribe Dan Primack says pressure from Wall Street is forcing Big Pharma to look to small startups to fill their pipeline rather than spending big bucks to develop new molecules internally. There are plenty of small companies to buy up right now, but that could change as small developers find it increasingly hard to land early investment money from venture capital funds. "What we face is a looming imbalance in which demand for new drugs far outstrips supply," notes Primack. Article

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.